ARTICLE | Clinical News
Seattle Genetics preclinical data
April 25, 2011 7:00 AM UTC
In a mouse xenograft model of breast cancer, Seattle Genetics' anti-LIV-1 antibody-drug conjugate (ADC) significantly delayed tumor growth vs. untreated controls. The ADC is composed of a humanized an...